Guide: How to cite a Dissertation in Memórias do Instituto Oswaldo Cruz style

Guide: How to cite a Dissertation in Memórias do Instituto Oswaldo Cruz style

Cite A Dissertation in Memórias do Instituto Oswaldo Cruz style

Ads keep us free. Upgrade to remove.

Use the following template to cite a dissertation using the Memórias do Instituto Oswaldo Cruz citation style. For help with other source types, like books, PDFs, or websites, check out our other guides. To have your reference list or bibliography automatically made for you, try our free citation generator.

Key:
Pink text = information that you will need to find from the source.
Black text = text required by the Memórias do Instituto Oswaldo Cruz style.

Reference list

Place this part in your bibliography or reference list at the end of your assignment.

Template:

Author Surname Author Initial Year Published. Title.

Example:

Pacher P, Batkai S, Kunos G 2006. The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacological Reviews 58: 389-462.

In-text citation

Place this part right after the quote or reference to the source in your assignment.

Template

(Author Surname Year Published)

Example

The recent identification of cannabinoid receptors and their endogenous lipid ligands has triggered an exponential growth of studies exploring the endocannabinoid system and its regulatory functions in health and disease. Such studies have been greatly facilitated by the introduction of selective cannabinoid receptor antagonists and inhibitors of endocannabinoid metabolism and transport, as well as mice deficient in cannabinoid receptors or the endocannabinoid-degrading enzyme fatty acid amidohydrolase. In the past decade, the endocannabinoid system has been implicated in a growing number of physiological functions, both in the central and peripheral nervous systems and in peripheral organs. More importantly, modulating the activity of the endocannabinoid system turned out to hold therapeutic promise in a wide range of disparate diseases and pathological conditions, ranging from mood and anxiety disorders, movement disorders such as Parkinson’s and Huntington’s disease, neuropathic pain, multiple sclerosis and spinal cord injury, to cancer, atherosclerosis, myocardial infarction, stroke, hypertension, glaucoma, obesity/metabolic syndrome, and osteoporosis, to name just a few. An impediment to the development of cannabinoid medications has been the socially unacceptable psychoactive properties of plant-derived or synthetic agonists, mediated by CB1 receptors. However, this problem does not arise when the therapeutic aim is achieved by treatment with a CB1 receptor antagonist, such as in obesity, and may also be absent when the action of endocannabinoids is enhanced indirectly through blocking their metabolism or transport. The use of selective CB2 receptor agonists, which lack psychoactive properties, could represent another promising avenue for certain conditions. The abuse potential of plant-derived cannabinoids may also be limited through the use of preparations with controlled composition and the careful selection of dose and route of administration. The growing number of preclinical studies and clinical trials with compounds that modulate the endocannabinoid system will probably result in novel therapeutic approaches in a number of diseases for which current treatments do not fully address the patients’ need. Here, we provide a comprehensive overview on the current state of knowledge of the endocannabinoid system as a target of pharmacotherapy. (Pacher et al. 2006)

Popular Memórias do Instituto Oswaldo Cruz Citation Guides

Other Memórias do Instituto Oswaldo Cruz Citation Guides

Join Us!

Save Time and Improve Your Marks with Cite This For Me

10,587 students joined last month!!

  • ✔ Save your bibliographies for longer
  • ✔ Quick and accurate citation program
  • ✔ Save time when referencing
  • ✔ Make your student life easy and fun
  • ✔ Use plagiarism checker
  • ✔ Create and edit multiple bibliographies
Join